PMID- 9458075
OWN - NLM
STAT- MEDLINE
DCOM- 19980224
LR  - 20071115
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 58
IP  - 3
DP  - 1998 Feb 1
TI  - FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma.
PG  - 380-3
AB  - Successful treatment of melanoma and lymphoma may result from the induction of 
      specific antitumor immunity. Dendritic cells (DCs) are powerful 
      antigen-presenting cells and show a remarkable capacity to stimulate 
      antigen-specific T-cell responses. Administration of FLT3 ligand (FL) results in 
      a reversible accumulation of functionally active DCs in both lymphoid and 
      nonlymphoid tissues. Therefore, we evaluated the possible antitumor effect of FL 
      in murine melanoma (B16 and CL8-1) and lymphoma (EL-4) models. In all 
      experiments, tumor growth was significantly inhibited by FL administration. 
      Analysis by immunohistochemistry revealed an increase in the DC accumulation 
      within B16 and EL-4 tumors after treatment with FL. No change was observed for 
      CL8-1 melanoma. These data suggest a potential role for FL in the immunotherapy 
      of malignant skin tumors and possible DC involvement in this effect.
FAU - Esche, C
AU  - Esche C
AD  - University of Pittsburgh Cancer Institute, Pennsylvania 15213, USA.
FAU - Subbotin, V M
AU  - Subbotin VM
FAU - Maliszewski, C
AU  - Maliszewski C
FAU - Lotze, M T
AU  - Lotze MT
FAU - Shurin, M R
AU  - Shurin MR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Immunologic Factors)
RN  - 0 (Membrane Proteins)
RN  - 0 (Recombinant Proteins)
RN  - 0 (flt3 ligand protein)
SB  - IM
MH  - Animals
MH  - Dendritic Cells/*drug effects/immunology
MH  - Drug Screening Assays, Antitumor
MH  - Immunity, Cellular/drug effects
MH  - Immunologic Factors/pharmacology/*therapeutic use
MH  - Lymphoma, T-Cell/immunology/*therapy
MH  - Male
MH  - Melanoma, Experimental/immunology/*therapy
MH  - Membrane Proteins/pharmacology/*therapeutic use
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neoplasm Transplantation
MH  - Recombinant Proteins/pharmacology/therapeutic use
MH  - Skin Neoplasms/immunology/*therapy
MH  - T-Lymphocytes/immunology
MH  - Tumor Cells, Cultured
EDAT- 1998/02/11 00:00
MHDA- 1998/02/11 00:01
CRDT- 1998/02/11 00:00
PHST- 1998/02/11 00:00 [pubmed]
PHST- 1998/02/11 00:01 [medline]
PHST- 1998/02/11 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1998 Feb 1;58(3):380-3.